Matches in SemOpenAlex for { <https://semopenalex.org/work/W118516757> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W118516757 endingPage "6" @default.
- W118516757 startingPage "151" @default.
- W118516757 abstract "To evaluate the feasibility, toxicity, and efficacy of adding vinorelbine to the paclitaxel/carboplatin combination in the treatment of advanced non-small cell lung cancer.Patients with advanced (stage IIIB/IV) non-small cell lung cancer who had received no previous chemotherapy were treated with the following three-drug regimen: paclitaxel, 200 mg/m2, 1-hour i.v. infusion, day 1; carboplatin, AUC 6.0 i.v., day 1; and vinorelbine, 22.5 mg/m2 i.v. days 1 and either 8 or 15. Treatment was repeated every 21 days. This phase II trial was conducted in a multicenter, community-based setting.Eighty-nine patients were treated with a median of four courses of therapy (range, one to eight). Thirty-one patients (35%) had major responses (two complete, 29 partial), and 36 patients (40%) had a minor response or stable disease. Actuarial median survival was 8.6 months; 1 year survival was 43%. Leukopenia was the major toxicity: 73% of patients had grade 3/4 toxicity, and 32 patients (36%) were hospitalized for neutropenia/fever (11% of total courses administered). Treatment-related death due to infection occurred in four patients (4%).This three-drug regimen is feasible and efficacious in the treatment of advanced non-small cell lung cancer. The addition of vinorelbine increases the incidence of severe leukopenia substantially when compared with the paclitaxel/carboplatin regimen. However, other toxicities are not markedly increased. Ongoing randomized trials will define the role of this regimen in the treatment of non-small cell lung cancer." @default.
- W118516757 created "2016-06-24" @default.
- W118516757 creator A5012217431 @default.
- W118516757 creator A5016234877 @default.
- W118516757 creator A5035473982 @default.
- W118516757 creator A5041294613 @default.
- W118516757 creator A5042449701 @default.
- W118516757 creator A5046682223 @default.
- W118516757 creator A5068323227 @default.
- W118516757 creator A5083212005 @default.
- W118516757 creator A5084010812 @default.
- W118516757 date "2000-07-06" @default.
- W118516757 modified "2023-09-23" @default.
- W118516757 title "Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network." @default.
- W118516757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10882330" @default.
- W118516757 hasPublicationYear "2000" @default.
- W118516757 type Work @default.
- W118516757 sameAs 118516757 @default.
- W118516757 citedByCount "3" @default.
- W118516757 countsByYear W1185167572016 @default.
- W118516757 crossrefType "journal-article" @default.
- W118516757 hasAuthorship W118516757A5012217431 @default.
- W118516757 hasAuthorship W118516757A5016234877 @default.
- W118516757 hasAuthorship W118516757A5035473982 @default.
- W118516757 hasAuthorship W118516757A5041294613 @default.
- W118516757 hasAuthorship W118516757A5042449701 @default.
- W118516757 hasAuthorship W118516757A5046682223 @default.
- W118516757 hasAuthorship W118516757A5068323227 @default.
- W118516757 hasAuthorship W118516757A5083212005 @default.
- W118516757 hasAuthorship W118516757A5084010812 @default.
- W118516757 hasConcept C126322002 @default.
- W118516757 hasConcept C141071460 @default.
- W118516757 hasConcept C143998085 @default.
- W118516757 hasConcept C2776256026 @default.
- W118516757 hasConcept C2776694085 @default.
- W118516757 hasConcept C2777063308 @default.
- W118516757 hasConcept C2777292972 @default.
- W118516757 hasConcept C2778119113 @default.
- W118516757 hasConcept C2778239845 @default.
- W118516757 hasConcept C2780350996 @default.
- W118516757 hasConcept C2780873365 @default.
- W118516757 hasConcept C2781413609 @default.
- W118516757 hasConcept C2781451048 @default.
- W118516757 hasConcept C71924100 @default.
- W118516757 hasConcept C90924648 @default.
- W118516757 hasConceptScore W118516757C126322002 @default.
- W118516757 hasConceptScore W118516757C141071460 @default.
- W118516757 hasConceptScore W118516757C143998085 @default.
- W118516757 hasConceptScore W118516757C2776256026 @default.
- W118516757 hasConceptScore W118516757C2776694085 @default.
- W118516757 hasConceptScore W118516757C2777063308 @default.
- W118516757 hasConceptScore W118516757C2777292972 @default.
- W118516757 hasConceptScore W118516757C2778119113 @default.
- W118516757 hasConceptScore W118516757C2778239845 @default.
- W118516757 hasConceptScore W118516757C2780350996 @default.
- W118516757 hasConceptScore W118516757C2780873365 @default.
- W118516757 hasConceptScore W118516757C2781413609 @default.
- W118516757 hasConceptScore W118516757C2781451048 @default.
- W118516757 hasConceptScore W118516757C71924100 @default.
- W118516757 hasConceptScore W118516757C90924648 @default.
- W118516757 hasIssue "3" @default.
- W118516757 hasLocation W1185167571 @default.
- W118516757 hasOpenAccess W118516757 @default.
- W118516757 hasPrimaryLocation W1185167571 @default.
- W118516757 hasRelatedWork W118516757 @default.
- W118516757 hasRelatedWork W1562964855 @default.
- W118516757 hasRelatedWork W1571466982 @default.
- W118516757 hasRelatedWork W1983784941 @default.
- W118516757 hasRelatedWork W2001963789 @default.
- W118516757 hasRelatedWork W2053432470 @default.
- W118516757 hasRelatedWork W2119659897 @default.
- W118516757 hasRelatedWork W2141969051 @default.
- W118516757 hasRelatedWork W2389873005 @default.
- W118516757 hasRelatedWork W2439707001 @default.
- W118516757 hasVolume "6" @default.
- W118516757 isParatext "false" @default.
- W118516757 isRetracted "false" @default.
- W118516757 magId "118516757" @default.
- W118516757 workType "article" @default.